A Multicenter Randomized Double-Blind Placebo-Controlled Parallel-Group Comparison Study in Patients with Non-Small Cell Lung Cancer-Cachexia

Trial Profile

A Multicenter Randomized Double-Blind Placebo-Controlled Parallel-Group Comparison Study in Patients with Non-Small Cell Lung Cancer-Cachexia

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Anamorelin (Primary)
  • Indications Cachexia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Ono Pharmaceutical
  • Most Recent Events

    • 04 Dec 2017 Results published in the Cancer
    • 11 Oct 2016 Primary endpoint (Change in LBM (measured by DXA)) has been met, according to the results presented at the 41st European Society for Medical Oncology Congress
    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top